The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Open accessAbstract
Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors (TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast, adverse events (AEs) are often reported as infrequent, minor, tolerable and manageable, but they are increasingly important as therapy is potentially lifelong and multiple TKIs are available. For this reason, the European LeukemiaNet panel for CML management recommendations presents an exhaustive and critical summary of AEs emerging during CML treatment, to assist their understanding, management and prevention. There are five major conclusions. First, the main purpose of CML treatment is the antileukemic effect. Suboptimal management of AEs must not compromise this first objective. Second, most patients will have AEs, usually early, mostly mild to moderate, and which will resolve spontaneously or are easily controlled by simple means. Third, reduction or interruption of treatment must only be done if optimal management of the AE cannot be accomplished in other ways, and frequent monitoring is needed to detect resolution of the AE as early as possible. Fourth, attention must be given to comorbidities and drug interactions, and to new events unrelated to TKIs that are inevitable during such a prolonged treatment. Fifth, some TKI-related AEs have emerged which were not predicted or detected in earlier studies, maybe because of suboptimal attention to or absence from the preclinical data. Overall, imatinib has demonstrated a good long-term safety profile, though recent findings suggest underestimation of symptom severity by physicians. Second and third generation TKIs have shown higher response rates, but have been associated with unexpected problems, some of which could be irreversible. We hope these recommendations will help to minimise adverse events, and we believe that an optimal management of them will be rewarded by better TKI compliance and thus better CML outcomes, together with better quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationRecommended standards for reports dealing with lower extremity ischemia: Revised version
Rutherford, R. B., Baker, J. D., Ernst, C., Johnston, K. W., Porter, J. M., Ahn, S., & Jones, D. N. (1997) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(97)70045-4 · Cited by 3,562
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Self-citationDasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Self-citationSevere Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Self-citationBaccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Self-citationBaccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Self-citationCardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Self-citationHochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.38 · Cited by 856
Self-citationHochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P. D., Etienne, G., Dorlhiac-Llacer, P. E., Clark, R. E., et al. (2016) · Leukemia · doi:10.1038/leu.2016.5 · Cited by 839
Self-citationPonatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769
Kantarjian, H. M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F.-E., O'Brien, S. G., Litzow, M., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080689 · Cited by 746
Self-citationAnderson, J. L., Halperin, J. L., Albert, N., Bozkurt, B., Brindis, R. G., Curtis, L. H., DeMets, D., Guyton, R. A., Hochman, J. S., Kovacs, R. J., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.004 · Cited by 664
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
Montani, D., Bergot, E., Günther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.079921 · Cited by 659
Deininger, M., O'Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., Radich, J. P., Hatfield, A. K., Mone, M., Filian, J., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1126.1126 · Cited by 616
Self-citationKantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610
Self-citationHochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., Facon, T., Goldberg, S. L., Cervantes, F., Niederwieser, D., et al. (2007) · Blood · doi:10.1182/blood-2006-09-047266 · Cited by 609
Self-citationCortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2018) · Blood · doi:10.1182/blood-2016-09-739086 · Cited by 592
Self-citationKantarjian, H. M., Hochhaus, A., Saglio, G., De Souza, C., Flinn, I. W., Stenke, L., Goh, Y.-T., Rosti, G., Nakamae, H., Gallagher, N. J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70201-7 · Cited by 513
Self-citationShah, N. P., Kantarjian, H. M., Kim, D.-W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9260 · Cited by 489
Self-citationCortes, J. E., Kim, D.-W., Kantarjian, H. M., Brümmendorf, T. H., Dyagil, I., Griskevicius, L., Malhotra, H., Powell, C., Gogat, K., Countouriotis, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7522 · Cited by 466
Self-citationCortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D.-W., Turkina, A. G., Shen, Z.-X., Pasquini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 463
Self-citationLarson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D.-W., Flinn, I. W., Kurokawa, M., Moiraghi, B., Yu, R., et al. (2012) · Leukemia · doi:10.1038/leu.2012.134 · Cited by 442
Self-citationGambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Self-citationPractical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib
Deininger, M. W. N., O’Brien, S. G., Ford, J. M., & Druker, B. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.143 · Cited by 402
Jabbour, E., Kantarjian, H. M., Saglio, G., Steegmann, J. L., Shah, N. P., Boqué, C., Chuah, C., Pavlovsky, C., Mayer, J., Cortes, J., et al. (2014) · Blood · doi:10.1182/blood-2013-06-511592 · Cited by 395
Self-citationKantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Giles, F., Rios, M. B., Shan, J., Letvak, L., Thomas, D., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3800 · Cited by 392
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 392
Self-citationQuintás-Cardama, A., Kantarjian, H., O'Brien, S., Borthakur, G., Bruzzi, J., Munden, R., & Cortes, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0329 · Cited by 388
Kantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Hochhaus, A., Radich, J. P., Saglio, G., et al. (2011) · Blood · doi:10.1182/blood-2010-03-277152 · Cited by 380
Self-citationKantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., Robak, T., Khoroshko, N., Masszi, T., Skotnicki, A., et al. (2007) · Blood · doi:10.1182/blood-2006-11-056028 · Cited by 377
Guilhot, F., Apperley, J., Kim, D.-W., Bullorsky, E. O., Baccarani, M., Roboz, G. J., Amadori, S., de Souza, C. A., Lipton, J. H., Hochhaus, A., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046839 · Cited by 371
Self-citationHochhaus, A., Baccarani, M., Deininger, M., Apperley, J. F., Lipton, J. H., Goldberg, S. L., Corm, S., Shah, N. P., Cervantes, F., Silver, R. T., et al. (2008) · Leukemia · doi:10.1038/leu.2008.84 · Cited by 352
Self-citationClonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
Mustjoki, S., Ekblom, M., Arstila, T. P., Dybedal, I., Epling-Burnette, P. K., Guilhot, F., Hjorth-Hansen, H., Höglund, M., Kovanen, P., Laurinolli, T., et al. (2009) · Leukemia · doi:10.1038/leu.2009.46 · Cited by 327
Self-citationKhoury, H. J., Cortes, J. E., Kantarjian, H. M., Gambacorti-Passerini, C., Baccarani, M., Kim, D.-W., Zaritskey, A., Countouriotis, A., Besson, N., Leip, E., et al. (2012) · Blood · doi:10.1182/blood-2011-11-390120 · Cited by 324
Self-citationHehlmann, R., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Müller, M. C., Pletsch, N., Proetel, U., Haferlach, C., Schlegelberger, B., Balleisen, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0598 · Cited by 323
Self-citationAltered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate
Berman, E., Nicolaides, M., Maki, R. G., Fleisher, M., Chanel, S., Scheu, K., Wilson, B.-A., Heller, G., & Sauter, N. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051140 · Cited by 319
Aichberger, K. J., Herndlhofer, S., Schernthaner, G., Schillinger, M., Mitterbauer‐Hohendanner, G., Sillaber, C., & Valent, P. (2011) · American Journal of Hematology · doi:10.1002/ajh.22037 · Cited by 296
Cardiotoxicity induced by tyrosine kinase inhibitors
Orphanos, G. S., Ioannidis, G. N., & Ardavanis, A. G. (2009) · Acta Oncologica · doi:10.1080/02841860903229124 · Cited by 284
Cortes, J. E., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D.-W., Pane, F., Pasquini, R., Goldberg, S. L., Kalaycio, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3724 · Cited by 284
Self-citationVascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Valent, P., Hadzijusufovic, E., Schernthaner, G.-H., Wolf, D., Rea, D., & le Coutre, P. (2015) · Blood · doi:10.1182/blood-2014-09-594432 · Cited by 283
Self-citationKalmanti, L., Saussele, S., Lauseker, M., Müller, M. C., Dietz, C. T., Heinrich, L., Hanfstein, B., Proetel, U., Fabarius, A., Krause, S. W., et al. (2015) · Leukemia · doi:10.1038/leu.2015.36 · Cited by 277
Self-citationEfficace, F., Baccarani, M., Breccia, M., Alimena, G., Rosti, G., Cottone, F., Deliliers, G. L., Baratè, C., Rossi, A. R., Fioritoni, G., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347575 · Cited by 257
Self-citationHepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Shah, R. R., Morganroth, J., & Shah, D. R. (2013) · Drug Safety · doi:10.1007/s40264-013-0048-4 · Cited by 252
Congestive heart failure is a rare event in patients receiving imatinib therapy
Atallah, E., Durand, J.-B., Kantarjian, H., & Cortes, J. (2007) · Blood · doi:10.1182/blood-2007-01-070144 · Cited by 252
Giles, F. J., le Coutre, P. D., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Hochhaus, A., Radich, J. P., Saglio, G., Hughes, T. P., et al. (2013) · Leukemia · doi:10.1038/leu.2012.181 · Cited by 251
Self-citationCorticosteroids can reverse severe imatinib-induced hepatotoxicity.
Ljungman, P. T., Perez-Bercoff, L., Jonsson, J., Avetisyan, G., Sparrelid, E., Aschan, J., Barkholt, L., Larsson, K., Winiarski, J., Yun, Z., et al. (2006) · PubMed · Cited by 245
Shah, N. P., Kim, D.-W., Kantarjian, H., Rousselot, P., Llacer, P. E. D., Enrico, A., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Muller, M. C., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.011452 · Cited by 244
Self-citationNilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Cortes, J. E., Jones, D., O'Brien, S., Jabbour, E., Konopleva, M., Ferrajoli, A., Kadia, T., Borthakur, G., Stigliano, D., Shan, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4896 · Cited by 244
Brave, M., Goodman, V., Kaminskas, E., Farrell, A., Timmer, W., Pope, S., Harapanhalli, R., Saber, H., Morse, D., Bullock, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4175 · Cited by 244
Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
Cortes, J. E., Jones, D., O'Brien, S., Jabbour, E., Ravandi, F., Koller, C., Borthakur, G., Walker, B., Zhao, W., Shan, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4920 · Cited by 241
Valeyrie, L., Bastuji-Garin, S., Revuz, J., Bachot, N., Wechsler, J., Berthaud, P., Tulliez, M., & Giraudier, S. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.44 · Cited by 234
Kim, T. D., Rea, D., Schwarz, M., Grille, P., Nicolini, F. E., Rosti, G., Levato, L., Giles, F. J., Dombret, H., Mirault, T., et al. (2013) · Leukemia · doi:10.1038/leu.2013.70 · Cited by 233
Self-citationGiles, F. J., Mauro, M. J., Hong, F., Ortmann, C.-E., McNeill, C., Woodman, R. C., Hochhaus, A., le Coutre, P. D., & Saglio, G. (2013) · Leukemia · doi:10.1038/leu.2013.69 · Cited by 216
Self-citationNilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Rosti, G., Palandri, F., Castagnetti, F., Breccia, M., Levato, L., Gugliotta, G., Capucci, A., Cedrone, M., Fava, C., Intermesoli, T., et al. (2009) · Blood · doi:10.1182/blood-2009-07-232595 · Cited by 210
Self-citationTyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia
Quintás-Cardama, A., Han, X., Kantarjian, H., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-09-180604 · Cited by 207
Shah, N. P., Guilhot, F., Cortes, J. E., Schiffer, C. A., le Coutre, P., Brümmendorf, T. H., Kantarjian, H. M., Hochhaus, A., Rousselot, P., Mohamed, H., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532341 · Cited by 200
Self-citationImatinib treatment: Specific issues related to safety, fertility, and pregnancy
Hensley, M. L., & Ford, J. M. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70016-x · Cited by 199
Brümmendorf, T. H., Cortes, J. E., de Souza, C. A., Guilhot, F., Duvillié, L., Pavlov, D., Gogat, K., Countouriotis, A. M., & Gambacorti‐Passerini, C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13108 · Cited by 194
Apperley, J. F., Cortes, J. E., Kim, D.-W., Roy, L., Roboz, G. J., Rosti, G., Bullorsky, E. O., Abruzzese, E., Hochhaus, A., Heim, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3339 · Cited by 194
Self-citationLung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia: A Case Series
Bergeron, A., Réa, D., Levy, V., Picard, C., Meignin, V., Tamburini, J., Bruzzoni-Giovanelli, H., Calvo, F., Tazi, A., & Rousselot, P. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-715cr · Cited by 184
Radich, J. P., Kopecky, K. J., Appelbaum, F. R., Kamel-Reid, S., Stock, W., Malnassy, G., Paietta, E., Wadleigh, M., Larson, R. A., Emanuel, P., et al. (2012) · Blood · doi:10.1182/blood-2012-02-410688 · Cited by 174
Dorer, D. J., Knickerbocker, R. K., Baccarani, M., Cortes, J. E., Hochhaus, A., Talpaz, M., & Haluska, F. G. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.07.007 · Cited by 166
Self-citationSevere Peripheral Arterial Disease During Nilotinib Therapy
Le Coutre, P., Rea, D., Abruzzese, E., Dombret, H., Trawinska, M. M., Herndlhofer, S., Dorken, B., & Valent, P. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr292 · Cited by 159
Self-citationAgostino, N. M., Chinchilli, V. M., Lynch, C. J., Koszyk-Szewczyk, A., Gingrich, R., Sivik, J. M., & Drabick, J. J. (2010) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155210378913 · Cited by 156
Porkka, K., Khoury, H. J., PAQUETTE, R. L., Matloub, Y., Sinha, R., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24734 · Cited by 152
Self-citationTyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
Shah, D. R., Shah, R. R., & Morganroth, J. (2013) · Drug Safety · doi:10.1007/s40264-013-0050-x · Cited by 150
Réa, D., Mirault, T., Cluzeau, T., Gautier, J., Guilhot, F., Dombret, H., & Messas, E. (2014) · Haematologica · doi:10.3324/haematol.2014.104075 · Cited by 146
Kim, D. H., Kamel‐Reid, S., Chang, H., Sutherland, R., Jung, C. W., Kim, H.-J., Lee, J.-J., & Lipton, J. H. (2008) · Haematologica · doi:10.3324/haematol.13151 · Cited by 145
Self-citationBleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
Quintás‐Cardama, A., Kantarjian, H. M., Ravandi, F., O'Brien, S. M., Thomas, D. M., Vidal‐Senmache, G., Wierda, W. G., Kornblau, S. M., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24257 · Cited by 144
de Lavallade, H., Punnialingam, S., Milojković, D., Bua, M., Khorashad, J. S., Gabriel, I. H., Chaidos, A., Olavarría, E., Goldman, J. M., Apperley, J. F., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07108.x · Cited by 141
Hazarika, M., Jiang, X., Liu, Q., Lee, S., Ramchandani, R. P., Garnett, C. E., Orr, M. S., Sridhara, R., Booth, B. P., Leighton, J. K., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0308 · Cited by 136
Guilhot, F., Hughes, T. P., Cortes, J. E., Druker, B. J., Baccarani, M., Gathmann, I., Hayes, M., Granvil, C. P., & Wang, Y. L. (2012) · Haematologica · doi:10.3324/haematol.2011.045666 · Cited by 134
Self-citationGratacap, M., Martin, V., Valera, M., Allart, S., Garcia, C., Siè, P., Récher, C., & Payrastre, B. (2009) · Blood · doi:10.1182/blood-2009-02-205328 · Cited by 132
Saglio, G. N., Hochhaus, A., Goh, Y. T., Masszi, T., Pasqüini, R., Maloisel, F., Erben, P., Cortes, J. E., PAQUETTE, R. L., Bradley‐Garelik, M. B., et al. (2010) · Cancer · doi:10.1002/cncr.25123 · Cited by 127
Self-citationSneed, T. B., Kantarjian, H. M., Talpaz, M., O'Brien, S. M., Rios, M. B., Bekele, B. N., Zhou, X., Resta, D. J., Wierda, W., Faderl, S. H., et al. (2003) · Cancer · doi:10.1002/cncr.11863 · Cited by 127
Practical management of tyrosine kinase inhibitor-associated side effects in GIST
Joensuu, H., Trent, J. C., & Reichardt, P. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.04.008 · Cited by 127
Cortes, J. E., Kantarjian, H. M., Goldberg, S. L., Powell, B. L., Giles, F. J., Wetzler, M., Akard, L. P., Burke, J. M., Kerr, R. O., Saleh, M. N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.3869 · Cited by 126
Amitay‐Laish, I., Stemmer, S. M., & Lacouture, M. E. (2011) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2011.01431.x · Cited by 125
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
Singer, J. B., Shou, Y., Giles, F. J., Kantarjian, H. M., Hsu, Y., Robeva, A., Rae, P., Weitzman, A., Meyer, J. M., Dugan, M. H., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404827 · Cited by 125
Johnson, F. M., Agrawal, S., Burris, H. A., Rosen, L. S., Dhillon, N., Hong, D. S., Blackwood‐Chirchir, A., Luo, F. R., Sy, O., Kaul, S., et al. (2010) · Cancer · doi:10.1002/cncr.24927 · Cited by 124
How I treat leukemia during pregnancy
Milojković, D., & Apperley, J. F. (2013) · Blood · doi:10.1182/blood-2013-08-283580 · Cited by 123
Scheinfeld, N. S. (2006) · PubMed · Cited by 118
Steegmann, J. L., Cervantes, F., le Coutre, P., Porkka, K., & Saglio, G. N. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.695779 · Cited by 115
Self-citationde Lavallade, H., Khoder, A., Hart, M., Sarvaria, A., Sekine, T., Alsuliman, A., Mielke, S., Bazeos, A., Stringaris, K., Ali, S., et al. (2013) · Blood · doi:10.1182/blood-2012-11-465039 · Cited by 110
Hochhaus, A., Rosti, G., Cross, N. C. P., Steegmann, J. L., le Coutre, P., Ossenkoppele, G. J., Petrov, L., Masszi, T., Hellmann, A., Griškevičius, L., et al. (2015) · Leukemia · doi:10.1038/leu.2015.270 · Cited by 110
Self-citationWang, J., Shen, Z., Saglio, G. N., Jin, J., Huang, H., Hu, Y., Du, X., Li, J., Meng, F., Zhu, H., et al. (2015) · Blood · doi:10.1182/blood-2014-09-601674 · Cited by 108
Self-citationIncidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
Kloth, J. S. L., Pagani, A., Verboom, M. C., Malovini, A. L., Napolitano, C., Kruit, W. H. J., Sleijfer, S., Steeghs, N., Zambelli, A., & Mathijssen, R. H. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.82 · Cited by 107
Rasheed, W. K., Flaim, B., & Seymour, J. F. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.09.026 · Cited by 106
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
Sillaber, C., Herrmann, H., Bennett, K. L., Rix, U., Baumgärtner, C., Böhm, A., Herndlhofer, S., Tschachler, E., Superti‐Furga, G., Jaeger, U., et al. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02206.x · Cited by 104
Kreutzman, A. S., Ladell, K., Koechel, C., Emma Gostick, D., Ekblom, M., Stenke, L., Melo, T., Einsele, H., Porkka, K., Price, D. A., et al. (2011) · Leukemia · doi:10.1038/leu.2011.135 · Cited by 101
Self-citationMattiuzzi, G. N., Cortes, J. E., Talpaz, M., Reuben, J. M., Rios, M. B., Shan, J., Kontoyiannis, D. P., Giles, F. J., RAAD, I. I., Verstovšek, S., et al. (2003) · PubMed · Cited by 101
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Hatfield, A. K., Owen, S., & Pilot, P. R. (2007) · Nature Medicine · doi:10.1038/nm0107-13a · Cited by 100
Zeiser, R., Youssef, S., Baker, J. B., Kambham, N., Steinman, L., & Negrin, R. S. (2007) · Blood · doi:10.1182/blood-2007-08-106005 · Cited by 99
Gynaecomastia in men with chronic myeloid leukaemia after imatinib
Gambacorti-Passerini, C. B., Tornaghi, L., Cavagnini, F., Rossi, P., Giraldi, F. P., Mariani, L., Cambiaghi, N., Pogliani, E., Corneo, G. M., & Gnessi, L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13554-4 · Cited by 98
Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis
Teo, Y. L., Ho, H. K., & Chan, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.09.004 · Cited by 98
Gallipoli, P., Pellicano, F., Morrison, H., Laidlaw, K. M. E., Allan, E. K., Bhatia, R., Copland, M., Jørgensen, H. G., & Holyoake, T. L. (2013) · Blood · doi:10.1182/blood-2013-02-485607 · Cited by 98
Dasatinib inhibits proinflammatory functions of mature human neutrophils
Futosi, K., Németh, T., Pick, R., Vántus, T., Walzog, B., & Mócsai, A. (2012) · Blood · doi:10.1182/blood-2011-07-369041 · Cited by 96
Imatinib Mesylate and Gray Hair
Étienne, G., Cony‐Makhoul, P., & Mahon, F. (2002) · New England Journal of Medicine · doi:10.1056/nejm200208083470614 · Cited by 95
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
Mustjoki, S. M., Auvinen, K., Kreutzman, A. S., Rousselot, P. H., Hernesniemi, S., Melo, T., Lahesmaa-Korpinen, A.-M., Hautaniemi, S., Bouchet, S., Molimard, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.348 · Cited by 93
Self-citationThe BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
Salih, J., Hilpert, J., Placke, T., Grünebach, F., Steinle, A., Salih, H. R., & Krusch, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25233 · Cited by 90
Tefferi, A., & Letendre, L. (2011) · American Journal of Hematology · doi:10.1002/ajh.22051 · Cited by 86
Kim, T. D., Schwarz, M., Nogai, H., Grille, P., Westermann, J., Plöckinger, U., Braun, D., Schweizer, U., Arnold, R., Dörken, B., et al. (2010) · Thyroid · doi:10.1089/thy.2010.0251 · Cited by 82
Self-citationImatinib-induced fatal acute liver failure
Ridruejo, E., Cacchione, R., Villamil, A. G., Marciano, S., Gadano, A. C., & Mandó, O. G. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i48.6608 · Cited by 76
Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival
Ranuncolo, S. M., Pittaluga, S., Evbuomwan, M. O., Jaffe, E. S., & Lewis, B. A. (2012) · Blood · doi:10.1182/blood-2012-01-405951 · Cited by 76
Imatinib mesylate as a cause of acute liver failure
Cross, T., Bagot, C. N., Portmann, B., Wendon, J. A., & Gillett, D. (2006) · American Journal of Hematology · doi:10.1002/ajh.20486 · Cited by 75
Levato, L., Cantaffa, R., Kropp, M. G., Magro, D., Piro, E., & Molica, S. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12096 · Cited by 75
Ohyashiki, K., Kuriyama, Y., Nakajima, A., Tauchi, T., Ito, Y., Miyazawa, H., Kimura, Y., Serizawa, H., & Ebihara, Y. (2002) · Leukemia · doi:10.1038/sj.leu.2402702 · Cited by 72
Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss
François, H., Coppo, P., Hayman, J.-P., Fouqueray, B. L., Mougenot, B., & Ronco, P. M. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.039 · Cited by 72
An evaluation of the cardiotoxicity of imatinib mesylate
Ribeiro, A. L. P., Marcolino, M. S., Bittencourt, H. N. D. S., Barbosa, M. M., Nunes, M. C. P., Xavier, V. F., & Clementino, N. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.03.020 · Cited by 71
Breccia, M., Latagliata, R., Stagno, F., Luciano, L., Gozzini, A., Castagnetti, F., Fava, C., Cavazzini, F., Annunziata, M., Rossi, A. R., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.041251 · Cited by 70
Self-citationBrazzelli, V., Grasso, V., & Borroni, G. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12172 · Cited by 69
Castagnetti, F., Palandri, F., Amabile, M., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Breccia, M., Cambrin, G. R., Stagno, F., et al. (2009) · Blood · doi:10.1182/blood-2007-08-103499 · Cited by 69
Self-citationExpanding Nilotinib Access in Clinical Trials (ENACT)
Nicolini, F. E., Turkina, A., Shen, Z., Gallagher, N. J., Jootar, S., Powell, B. L., Souza, C. A. D., Zheng, M., Szczudlo, T. K., & le Coutre, P. (2011) · Cancer · doi:10.1002/cncr.26249 · Cited by 68
Ho, W. L., Wong, H., & Yau, T. C. C. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2012.02518.x · Cited by 67
Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
Pou, M., Saval, N., Vera, M., Saurina, A., Solé, M., Cervantes, F., & Botey, A. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000079140 · Cited by 66
Managing cutaneous reactions to imatinib therapy
Rule, S. A., O’Brien, S. G., & Crossman, L. C. (2002) · Blood · doi:10.1182/blood-2002-08-2431 · Cited by 66
Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
Iyoda, M., Shibata, T., Hirai, Y., Kuno, Y., & Akizawa, T. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111158 · Cited by 66
Deininger, M. W., Kopecky, K. J., Radich, J. P., Kamel‐Reid, S., Stock, W., Paietta, E. M., Emanuel, P. D., Tallman, M. S., Wadleigh, M., Larson, R. A., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12618 · Cited by 65
Breccia, M., Muscaritoli, M., Gentilini, F., Latagliata, R., Carmosino, I., Fanelli, F. R., & Alimena, G. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.01.024 · Cited by 65
Self-citationHypersensitivity Pneumonitis Related to Imatinib Mesylate
Bergeron, A., Bergot, E., Vilela, G. D. B., Adès, L., Devergié, A., Espérou, H., Socié, G., Calvo, F. M., Gluckman, É., Ribaud, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.99.179 · Cited by 64
Latagliata, R., Breccia, M., Fava, C., Stagno, F., Tiribelli, M., Luciano, L., Gozzini, A., Gugliotta, G., Annunziata, M., Cavazzini, F., et al. (2012) · Hematological Oncology · doi:10.1002/hon.2020 · Cited by 64
Self-citationQuintás‐Cardama, A., Kantarjian, H. M., O'Brien, S. M., et al. (2004) · Cancer · doi:10.1002/cncr.20285 · Cited by 63
Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia
Réa, D. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2318-y · Cited by 62
On behalf of the TOPS investigators, Baccarani, M., Druker, B. J., et al. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1566-2 · Cited by 60
Self-citationClinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
Nagata, Y., Ohashi, K., Fukuda, S., Kamata, N., Akiyama, H., & Sakamaki, H. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0565-1 · Cited by 60
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Rosti, G., Martinelli, G., & Baccarani, M. (2007) · Nature Medicine · doi:10.1038/nm0107-15a · Cited by 59
Self-citationFatal hepatic necrosis following imatinib mesylate therapy
Lin, N., Sarantopoulos, S., Stone, J. R., Galinsky, I. A., Stone, R. M., DeAngelo, D. J., & Soiffer, R. J. (2003) · Blood · doi:10.1182/blood-2003-07-2323 · Cited by 58
Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors
Tonyalı, Ö., Çoşkun, U., Yıldız, R., Karakan, T., Demırcı, U., Akyürek, N., Beneklı, M., & Buyukberber, S. (2009) · Medical Oncology · doi:10.1007/s12032-009-9284-y · Cited by 57
Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Prostate Cancer
Foringer, J. R., Verani, R. R., Tjia, V. M., et al. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g131 · Cited by 57
Imatinib (Gleevec)-induced hepatotoxicity.
Ayoub, W. S., Geller, S. A., Tran, T. T., Martin, P., Vierling, J. M., & Poordad, F. F. (2005) · PubMed · Cited by 56
Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia
Babu, K. G., Attili, V. S. S., Bapsy, P. P., & Anupama, G. (2007) · International Ophthalmology · doi:10.1007/s10792-007-9038-9 · Cited by 55
Breccia, M., Muscaritoli, M., Cannella, L., Stefanizzi, C., Frustaci, A. M., & Alimena, G. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.01.015 · Cited by 54
Self-citationPeriorbital Oedema and epiphora as ocular side effects of imatinib Mesylate (Gleevec)
Esmaeli, B., Diba, R., Ahmadi, M., Saadati, H. G., Faustina, M., Shepler, T. R., Talpaz, M., Fraunfelder, R. W., Rios, M. B., & Kantarjian, H. M. (2004) · Eye · doi:10.1038/sj.eye.6701315 · Cited by 53
Dasatinib treatment for Philadelphia chromosome‐positive leukemias
Khoury, H. J., Guilhot, F., Hughes, T. P., Kim, D., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24155 · Cited by 53
Self-citationRaisi‐Estabragh, Z., Knight, K., Watmough, S. J., Lane, S., Vinjamuri, S., Hart, G., & Clark, R. E. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.08.020 · Cited by 53
Self-citationEfficace, F., Breccia, M., Saußele, S., Kossak-Roth, U., Cardoni, A., Caocci, G., Chie, W., Naeem, A., Nicolatou‐Galitis, O., Cocks, K., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1458-6 · Cited by 52
Self-citationRenal failure associated with tyrosine kinase inhibitors—Case report and review of the literature
Gafter‐Gvili, A., Ram, R., Gafter, U., Shpilberg, O., & Raanani, P. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.07.009 · Cited by 52
Histological features of acute hepatitis after imatinib mesylate treatment
James, C., Trouette, H., Marit, G., Cony‐Makhoul, P., & Mahon, F. (2003) · Leukemia · doi:10.1038/sj.leu.2402910 · Cited by 52
La Rosée, P., Martiat, P., Leitner, A., Klag, T., Müller, M. C., Erben, P., Schenk, T., Saussele, S., & Hochhaus, A. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1769-2 · Cited by 50
Self-citationSeggewiss, R., Price, D. A., & Purbhoo, M. A. (2008) · Cytotherapy · doi:10.1080/14653240802317639 · Cited by 50
Cerebral oedema as a possible complication of treatment with imatinib
Ebnöther, M., Stentoft, J., Ford, J., Buhl, L., & Gratwohl, A. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08616-6 · Cited by 49
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Atallah, E. L., Kantarjian, H. M., & Cortes, J. E. (2007) · Nature Medicine · doi:10.1038/nm0107-14 · Cited by 49
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Gambacorti, C., Tornaghi, L., Franceschino, A., Piazza, R., Corneo, G. M., & Pogliani, E. (2007) · Nature Medicine · doi:10.1038/nm0107-13b · Cited by 48
Gottardi, M., Manzato, E., & Gherlinzoni, F. (2005) · New England Journal of Medicine · doi:10.1056/nejmc052500 · Cited by 47
Knickerbocker, R. K., Dorer, D. J., Haluska, F. G., Baccarani, M., Cortes, J. E., Hochhaus, A., & Talpaz, M. (2014) · Blood · doi:10.1182/blood.v124.21.4546.4546 · Cited by 46
Self-citationKikuchi, S., Muroi, K., Takahashi, S., Kawano-Yamamoto, C., Takatoku, M., Miyazato, A., Nagai, T., Mori, M., Komatsu, N., & Ozawa, K. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190412331272721 · Cited by 45
Osorio, S., Noblejas, A. G., Durán, A., & Steegmann, J. L. (2006) · American Journal of Hematology · doi:10.1002/ajh.20778 · Cited by 45
Self-citationDasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect?
Paydaş, S. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.10.005 · Cited by 44
Réa, D., Mirault, T., Raffoux, E., Boissel, N., Andreoli, A., Rousselot, P. H., Dombret, H., & Messas, E. (2014) · Leukemia · doi:10.1038/leu.2014.342 · Cited by 40
Al‐Aly, Z., Ashley, J. M. P., Gellens, M., & González, E. A. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.12.017 · Cited by 40
Góra‐Tybor, J., Mędraś, E., Całbecka, M., Kołkowska‐Leśniak, A., Ponikowska-Szyba, E., Robak, T., & Jamroziak, K. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.994205 · Cited by 40
Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia
Daniels, J. M. A., Noordegraaf, A. V., Janssen, J. J. W. M., Postmus, P. E., & van Altena, R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00025408 · Cited by 39
Breccia, M., & Alimena, G. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.01.021 · Cited by 38
Self-citationPalandri, F., Castagnetti, F., Soverini, S., Poerio, A., Gugliotta, G., Luatti, S., Amabile, M., Martinelli, G., Rosti, G., & Baccarani, M. (2009) · Haematologica · doi:10.3324/haematol.2009.010496 · Cited by 38
Self-citationLarson, R. A., Coutre, P. D. L., Reiffers, J. J., Hughes, T. P., Saglio, G. N., Edrich, P., Hoenekopp, A., Gallagher, N. J., Kantarjian, H. M., & Hochhaus, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.6501 · Cited by 38
Self-citationReactivation of chronic hepatitis B infection related to imatinib mesylate therapy
Lakhani, S., Davidson, L., Priebat, D. A., et al. (2008) · Hepatology International · doi:10.1007/s12072-008-9099-5 · Cited by 37
Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia
Caocci, G., Atzeni, S., Orrù, N., Azzena, L., Martorana, L., Littera, R., Ledda, A., & Nasa, G. L. (2008) · Leukemia · doi:10.1038/leu.2008.106 · Cited by 36
Nicolini, F. E., Masszi, T., Shen, Z., Gallagher, N. J., Jootar, S., Powell, B. L., Dorlhiac‐Llacer, P. E., Zheng, M., Szczudlo, T. K., & Turkina, A. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.627480 · Cited by 36
Franceschino, A., Tornaghi, L., Benemacher, V., Assouline, S. E., & Gambacorti-Passerini, C. B. (2008) · Haematologica · doi:10.3324/haematol.11680 · Cited by 36
Holstein, S. A., Stokes, J. B., & Hohl, R. J. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.07.029 · Cited by 34
Saglio, G. N., Larson, R. A., Hughes, T. P., Issaragrisil, S., Turkina, A., Marin, D., Zanichelli, M. A., Shibayama, H., Kalaycio, M. E., Huguet, F., et al. (2010) · Blood · doi:10.1182/blood.v116.21.3430.3430 · Cited by 34
Self-citationCortes, J. E., Hochhaus, A., Kim, D., Shah, N. P., Mayer, J., Rowlings, P., Nakamae, H., Bradley‐Garelik, M. B., Mohamed, H., Kantarjian, H. M., et al. (2013) · Blood · doi:10.1182/blood.v122.21.653.653 · Cited by 33
Self-citationRosti, G., Castagnetti, F., Gugliotta, G., Palandri, F., & Baccarani, M. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.07.004 · Cited by 33
Self-citationAcute Renal Failure under Dasatinib Therapy
Özkurt, S., Temiz, G., Açıkalın, M. F., & Soydan, M. (2010) · Renal Failure · doi:10.3109/08860220903391226 · Cited by 33
Berman, E., Girotra, M., Cheng, C., Chanel, S. M., Maki, R. G., Shelat, M., Strausś, H. W., Fleisher, M., Heller, G., & Farooki, A. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.02.005 · Cited by 32
Mirault, T., Réa, D., Azarine, A., & Messas, E. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12367 · Cited by 32
Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib
Mayer, K. T., Gielen, G. H., Willinek, W. A., Muller, M. C., & Wolf, D. G. F. (2013) · Leukemia · doi:10.1038/leu.2013.320 · Cited by 31
Dogan, S. S., & Esmaeli, B. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.11.003 · Cited by 31
Lee, S. J., Jung, C. W., Kim, D., Lee, K., Sohn, S. K., Kwak, J., Kim, H., Kim, I. H., Park, S., & Kim, D. H. (2011) · American Journal of Hematology · doi:10.1002/ajh.21980 · Cited by 30
Self-citationBrazzelli, V., Prestinari, F., Barbagallo, T., Rona, C., Orlandi, E. M., Passamonti, F., Locatelli, F., Zecca, M., Villani, S., & Borroni, G. (2006) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2006.01981.x · Cited by 28
Kim, D.-H., Goh, H., Kim, S., Cho, B., & Kim, D.-W. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0921-9 · Cited by 28
Self-citationSonnichsen, D. S., Dorer, D. J., Cortes, J. E., Talpaz, M., Deininger, M. W., Shah, N. P., Kantarjian, H. M., Bixby, D. L., Mauro, M. J., Flinn, I. W., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2160-7 · Cited by 27
Activity and tolerability of nilotinib
Koren‐Michowitz, M., le Coutre, P., Duyster, J., Scheid, C., Panayiotidis, P. G., Prejzner, W., Rowe, J. M., Schwarz, M., Goldschmidt, N., & Nagler, A. (2010) · Cancer · doi:10.1002/cncr.25351 · Cited by 26
Khoury, H. J., Goldberg, S. L., Mauro, M. J., Stone, R. M., Matloub, Y., Chen, T., & Guilhot, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.7015 · Cited by 25
Self-citationSanchez-Guijo, F. M., Durán, S., Galende, J., Boqué, C., Nieto, J. B., Balanzat, J., Gracia, A., García, I., Avellaneda-Molina, C., Moreno, M.-V., et al. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.01.017 · Cited by 23
Breccia, M., & Alimena, G. (2011) · BioDrugs · doi:10.2165/11591840-000000000-00000 · Cited by 22
Self-citationHypolipemiant besides antileukemic effect of imatinib mesylate
Gologan, R., Constantinescu, G., Georgescu, D. G., Ostroveanu, D., Vasilache, D., Dobrea, C. M., Iancu, D., & Popov, V. M. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.02.024 · Cited by 20
Réa, D., Gautier, J., Breccia, M., Saglio, G. N., Hughes, T. P., Kantarjian, H. M., Kemp, C. N., Gao, H., Piccolo, C. M., Larson, R. A., et al. (2012) · Blood · doi:10.1182/blood.v120.21.1686.1686 · Cited by 20
Self-citationHiwase, D., Yeung, D. T. O., Carne, L., Ross, D. M., Grigg, A., & Hughes, T. P. (2013) · Blood · doi:10.1182/blood.v122.21.1503.1503 · Cited by 19
Peripheral neuropathy as an adverse effect of imatinib therapy
Chakupurakal, G., Etti, R. J., & Murray, J. A. H. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.085936 · Cited by 17
Nilotinib in a Patient With Postnecrotic Liver Cirrhosis Related to Imatinib
Spataro, V. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5359 · Cited by 15
Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity
Harbaum, L., Marx, A. H., Goekkurt, E., et al. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1474-x · Cited by 14
Dasatinib and Chronic Myeloid Leukemia: Two-Year Follow-up in Eight Clinical Trials
Pavlů, J., & Marín, D. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.n.083 · Cited by 14
Go, S. W., Kim, B. K., Lee, S. H., et al. (2013) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2013.75.6.256 · Cited by 14
Kim, S., Kim, H. J., Kwak, J., Kim, J. S., Mun, Y., Park, J. S., Sohn, S. K., & Kim, D. (2012) · Blood · doi:10.1182/blood.v120.21.3738.3738 · Cited by 14
Self-citationKaiafa, G. D., Kakaletsis, N., Savopoulos, C., Perifanis, V., Giannouli, A., Papadopoulos, N., Zisekas, S., & Hatzitolios, A. I. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12107 · Cited by 13
Ross, D. M. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.02028.x · Cited by 12
le Coutre, P., Giles, F. J., Hochhaus, A., Martinelli, G., Wang, J. J., Passos, V. Q., Kayath, M. J., Baccarani, M., & Kantarjian, H. M. (2007) · Blood · doi:10.1182/blood.v110.11.4588.4588 · Cited by 11
Self-citationAgaimy, A., Brueckl, V., Schmidt, D., Krieg, S., Ullrich, E., & Meidenbauer, N. (2013) · Case Reports in Oncology · doi:10.1159/000348712 · Cited by 5
Cited by
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
Self-citationCortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2018) · Blood · doi:10.1182/blood-2016-09-739086 · Cited by 592
Self-citationShyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y.-T., Talpaz, M., Hochhaus, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902328 · Cited by 471
Self-citationPast, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Rossari, F., Minutolo, F., & Orciuolo, E. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0624-2 · Cited by 371
Metadata
- Authors
- Steegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., García-Gutiérrez, V, Hochhaus, A., Kim, D.-W., Kim, T. D., Khoury, H. J., Le Coutre, P., Mayer, J., Milojkovic, D., Porkka, K., Rea, D., Rosti, G., Saussele, S., Hehlmann, R., & Clark, R. E.
- Venue
- Leukemia
- Published
- 2016-04-28
- Volume
- 30
- Issue
- 8
- Pages
- 1648-1671
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2343511371
- Cited by
- 482
- References
- 199
- FWCI
- 43.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.